A drug information module design for a computerized pharmacy subsystem. by Mohr, Paul Robert
Lehigh University
Lehigh Preserve
Theses and Dissertations
1-1-1978
A drug information module design for a
computerized pharmacy subsystem.
Paul Robert Mohr
Follow this and additional works at: http://preserve.lehigh.edu/etd
Part of the Industrial Engineering Commons
This Thesis is brought to you for free and open access by Lehigh Preserve. It has been accepted for inclusion in Theses and Dissertations by an
authorized administrator of Lehigh Preserve. For more information, please contact preserve@lehigh.edu.
Recommended Citation
Mohr, Paul Robert, "A drug information module design for a computerized pharmacy subsystem." (1978). Theses and Dissertations.
Paper 2121.
A DRUG INFORMATION MODULE DESIGN FOR 
A COMPUTERIZED PHARMACY SUBSYSTF.M 
by 
Paul Robert Mohr 
A Thesis 
Presented to the Graduate Committee 
of Lehigh University 
in Candidacy for the Degree of 
Master of Science 
in 
Industrial Engineering 
Lehigh University 
1978 
ProQuest Number: EP76394 
All rights reserved 
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted. 
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed, 
a note will indicate the deletion. 
uest 
ProQuest EP76394 
Published by ProQuest LLC (2015). Copyright of the Dissertation is held by the Author. 
All rights reserved. 
This work is protected against unauthorized copying under Title 17, United States Code 
Microform Edition © ProQuest LLC. 
ProQuest LLC. 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346 
CERTIFICATE OF APPROVAL 
This, thesis is accepted and approved in partial 
fulfillment of the requirements for the degree of 
Master of Science. 
■???«« -i-./rsi a
-iH* te 
Chairman of  <;he  Department 
istrial   Ei of   Indus ngineering 
ii 
ACKNOWLEDGEMENTS 
/ 
The author acknowledges the assistance of 
Professor L. Long of Lehigh University, and R. Winner 
of the Allcntown-Sacred Heart Computer Center in the 
preparation of this thesis. 
k 
111 
/ 
TABLE OF CONTENTS 
Page 
ABSTRACT 1 
CHAPTER 1 - THESIS GOALS AND BACKGROUND       3 
l.A Computer Applications in 
Hospitals       5 
l.B Pharmacy Subsystem       8 
l.C Medication Monitoring - 
Drug Information      11 
l.D Allentown-Sacred Heart 
Hospital Computer Center      13 
CHAPTER 2 - CURRENT APPROACHES TO 
DRUG INFORMATION SYSTEMS      15 
2.A The B-D Spear Pharmacy 
Subsystem 830/MEDIPHOR 
Data Base      15 
2.B The MEDITECH Pharmacy 
Subsystem      21 
2.C Pharmacy Subsystem Drug 
Interaction Summary     24 
CHAPTER 3 - DRUG INFORMATION MODULE - 
USER ANALYSIS      27 
3.A The Drug Information 
Module User     27 
iv 
TABLE OF CONTENTS (Cont'd) 
i 
3.B Medication Order Process 
Page 
in the Pharmacy  29 
3.C DIM-Related Medication 
Order Processes  41 
3.D Drug Information Required 
for the DIM  47 
CHAPTER 4 - THE DRUG INTERACTION/INFORMATION 
DATA BASE  51 
4.A  Information Category  51 
4.B Formulary Subset  52 
4.C Drug-Interaction Subset  54 
4.D Drug-Interaction Subset 
Source Conversion  56 
4.E Drug-Information Subset  58 
4.F Drug-Information Subset 
Source Conversion  59 
4.G DIM Data Base Organization  60 
CHAPTER 5 - DRUG INFORMATION MODULE 
DESIGN SPECIFICATIONS  63 
5.A DIM Flowchart - Figure 5.1  63 
5.B DIM Data Base Schema  74 
5.C Design Assumptions  77 
I 
TABLE OF CONTENTS (Cont'd) 
Page 
5.D  Implementation Constraints  79 
5.E Controls  81 
5.F Back-Up  83 
5.G Conversion and Implementation.. 84 
CHAPTER 6 - DIM MOCK WALK-THROUGH  89 
6.A Mock-Up Objective  89 
6.B  Direct Allergic Reaction  90 
6.C Cross-Sensitivity Reaction  91 
6.D Drug-Drug Interaction  93 
6.E Mock-Up Results  95 
CHAPTER 7 - COST/BENEFIT ANALYSIS  98 
7.A Development Costs  98 
7.B Operation Costs  102 
7.C Tangible Benefits  103 
7.D  Intangible Benefits  104 
CHAPTER 8 - SUMMARY  107 
REFERENCES  108 
APPENDIX A  LIST OF ABBREVIATIONS  110 
VITA  112 
Vi 
<& 
LIST OF TABLES 
Table Pago 
2.1      System Summary 26 
6.1      Drug-Drug Interaction Mock-Upo 97 
vii 
LIST OF FIGURES 
Figure Pago 
1.1 DIM Boundaries 4 
2.1 Sample System 830 Output 19 
2.2 Sample System 830 Output 20 
3.1a Medication Order Process 30 
3.1b Medication Order Process (cont'd) 31 
3.2a Doctor's Order Sheet 32 
3.2b Doctor's Order Sheet Entries 33 
3.3a Pharmacy I.V. Profile 35 
3.3b Pharmacy I.V. Profile Entries 36 
3.4a Pharmacy Medication Profile 38 
3.4b Pharmacy Medication Profile Entries 39 
3.5a Medication Order Review Process 45 
3.5b Medication Order Review Process 
(cont'd) 46 
4.1 Overall DIM Data Base Organization 61 
5.1a Overall DIM Flowchart 64 
5.1b Overall DIM Flowchart (cont'd) 65 
5.1c Overall DIM Flowchart (cont'd) 66 
5.Id Overall DIM Flowchart (cont'd) 67 
5.1e Overall DIM Flowchart (cont'd) 68 
5.2 DIM Data Base Schema 75 
5.3 Conversion & Implementation Schedule   86 
viii 
ABSTRACT 
,The utility of a computerized Pharmacy Subsys- 
tem for a centralized hospital pharmacy may be increased 
by a Drug Information Module (DIM) to assist the staff 
pharmacist validate Medication Orders.  A properly 
designed DIM can access a patient allergy/medication 
history, and compare the history with a new patient Med- 
ication Order to detect potential allergic reactions, 
or drug-drug interactions that may be caused by the Med- 
ication Order.  In addition, the drug data base required 
for DIM operation may be used to provide on-line, pre- 
prescription drug information to the hospital physician. 
For design purposes, the primary DIM user 
should be defined to be the hospital staff pharmacist, 
in order to provide a stable user-population with high- 
level exposure to the DIM operation. 
Analysis indicates that to validate a Medica- 
tion Order, the staff pharmacist converts both the Medi- 
cation Order and the patient allergy/medication history 
to two drug-Family profiles that represent the active 
drug ingredients.  THe<-profiles are compared for an ele- 
ment match, which would indicate a potential allergic 
reaction.  To detect potential drug-drug interactions, 
the pharmacist generates all feasible drug-Family pairs 
with an element from the Medication Order profilo, and 
an element from the patient history profile, and 
attempts to identify any known interactive pairs.  A 
Medication Order that may cause either type of reaction/ 
interaction is verified with the writing physician and 
possibly modified. 
It is possible to design a DIM to interface 
with the Pharmacy Subsystem and simulate this process to 
increase the accuracy and speed with which a Medication 
Order is verified.  The design is feasible, and can 
increase the effectiveness of chemotherapy in health- 
care. 
a      CHAPTER I 
, THESIS GOALS 
The Allentown-Sacred Heart (ASH) Hospital is 
currently in the design stage of a Pharmacy Subsystom 
for a totally computerized Hospital Information System 
(HIS) that will encompass several hospital departments 
such as the pharmacy, laboratories, clinics, etc.  From 
initial pharmacy work-process investigation, it appears 
that the effect of the Pharmacy Subsystem may be greatly 
enhanced if it contains a Drug Information Module (DIM) 
to apply EDP resources to tasks that require a large 
volume of drug information be repeatedly and accurately 
accessed.  In particular, since the Pharmacy Subsystem 
must process Medication Orders and store patient medi- 
cation records-- for inventory and billing purposes — 
it is logical to consider the' use of a DIM in the Sub- 
system to monitor the technical utilization of pharmacy- 
i8oued drugs and assist with the Medidation Order 
validation process now performed in the pharmacy to 
detect drug therapy interactions that might be harmful 
to the patient.  To do this, the DIM would access 
Medication Orders, patient medication records, a drug 
information data base, and then apply decision rules 
that simulate the existing validation process.  The DIM 
boundaries, relative to the Pharmacy Subsystem, are 
indicated in Fig. 1.1: 
Figure 1.1 
DIM Boundaries 
J>J>L 7 
A 
To generate DIM design specifications, parameters such 
as users, decision rules, and required input/output data 
must be defined for the ASH environment, a process that 
must: 
1. examine the state of the art of current drug 
information processes. 
2. identify the potential DIM users in the ASH 
Hospital. 
3. define the functions that the DIM must provide 
the usors. 
4. create a conceptual view of the data required 
i 
for DIM operation. 
5. identify alternative sources for DIM data, and 
indicate how this data may be organized into a 
DIM data base. 
6. establish procedures to maintain the DIM data 
base and ensure data base integrity. 
7. mock-up DIM operation to indicate user response 
and design performance. 
8. perform a DIM cost/benefit .analysis. 
This project accomplishes each task, and results in 
design specifications for a DIM suitable to the users, 
the ASH Computer Center resources, and the total HIS 
effort. 
BACKGROUND 
A.   Computer Applications in Hospitals. 
The advantages of'speed, accuracy, and long- 
range economy inherent in a computerized information 
system can help hospitals deliver better health-care at 
a lower per-patient cost— critical factors in today's 
health-care environment, with medical costs which rise 
rapidly, and a larger, better-informed public that 
1 
expect8 high-quality medical care.  Several areas may be 
readily identified where an niS can improve health- 
i 
care systems performance. 
An HIS can reduce hospital costs because it 
can quickly, efficiently, and reliably integrate data 
sources and*information needs.  Several studies 
(Jydstrup, 1;  Richert, 2;  Jackson, 3;  Van Brunt, 4) 
show that 25-40% of daily hospital costs are directly 
related to information handling processes— transcribing, 
copying, filing, retrieving, and distributing intra- 
hospital documents —that can benefit from computer- 
systems assistance.  In addition, professional produc- 
tivity lost because of delays and inadequacies in 
manual systems must also be considered. 
In 1967, Barnett et al. (5) reported that 
each day in the 1100-bed Massachusetts General Hospital 
in Boston, more than: 
• 2,000 lab tests are performed. 
• 7,000 doctors' orders are executed. 
• 60,000 drugs and treatments are administered. 
They estimated that more than 100,000 items of infor- 
mation, such as medication, lab, and treatment orders 
and administrative patient-data, are recorded daily. 
Furthermore, 1.6 million patient-records are on file, 
and 50,000 patients are added yearly.  This rate of 
i 
data flow is unlikely to diminish, since population and 
hoepitalieation benefits are increasing, and medical 
treatment is becoming more complex.  As this already 
large data volumo increases, it should be easier to 
cost-justify computer techniques to process the sheer 
bulk of this data for the information-intensive health- 
care industry. 
Critical medical records are seldom available 
in crises, because manual systems are slow, and records 
axe often scattered among hospitals, clinics, and 
physicians.  In addition, with scattered records, it is 
impractical to use historical patient data (trending) 
to identify potential health problems, or for medical 
research.  An HIS can provide the speed, versatility, 
and data organization necessary to increase the effective 
use of medical data. 
Accuracy is critical in medical information, 
yet Raymond (6) reports that as many as 20% of laboratory 
test orders and results contain at least one error 
attributed to manual data transcribing and handling. An 
HIS can reduce the overall medical data error-rate 
because it can reduce the extent of manual interaction 
with data, and provide a moans to check for errors as 
data are entered. 
i 
As seen above, there are many areas in a 
hospital information environment where an HIS can be 
effective in improving data use.  A study (7) performed 
by the D.P. Management Corporation, a computer systems 
consulting firm, to develop strategies for managing the 
evolution of hospital computer technologyt   indicated 
that a Pharmacy Subsystem had a huge relative net value 
of the computer application areas commonly installed or 
considered for development by hospitals.  The ASH 
Computer Center verified this observation for their 
hospital environment with an analysis that considered 
the volume and relative dollar value of the data 
processes performed by the major hospital departments. 
Consequently, the Pharmacy Subsystem was given a high 
priority in the HIS development. 
B.   Pharmacy Subsystem. 
A Computerized Pharmacy Subsystem (CPS) can 
be used to increase the effectiveness of four major 
pharmacy tasks: ( 
• inventory 
• narcotics control 
• decreasing lost charges. 
• medication monitoring. 
i 
A CPS can log in received drugs, adjust 
inventory levels as drugs are charged out, and produce 
periodic shelf-stock reports to assist the pharmacy 
staff with the inventory and purchasing tasks.  This can 
be critical, since an average 4 50-bed hospital pharmacy 
receives approximately 300,000 drug orders per-year 
(American Hospital Association, 8), and each drug order 
is a request for the correct medication, in proper 
quantity, with the timely delivery to the user.  As 
drug costs and volume increase, effective pharmacy 
purchasing and inventory control become necessary in 
pharmacy operation.  In addition, since pharmacists are 
responsible for part of the pharmacy clerical work, the 
reduced personnel requirements of a CPS allow an increase 
in their technical productivity— filling prescriptions, 
medication monitoring, etc. 
A CPS can reduce narcotic control man-hour 
requirements and error-rate.  For several years, federal 
and state laws have required special narcotic handling 
in hospitals, and recent laws have expanded the number 
of drugs under control, which increases the associated 
administrative workload. Effective narcotic regulation 
requires volumes of paperwork; rcceival records, perpet- 
ual inventory, drug requisitions, dispositions, ad- 
ministrations, credits, and returns are typical narcotic 
controls that may be processed and verified by a CPS 
rather than a manual system. 
A CPS can reduce lost charges in the pharmacy. 
Lost charges— services not billed to the patient through 
a failure to input a charge into the billing system —can 
lose significant hospital revenue.  When a computerized 
Hospital Information System with a CPS was implemented, 
one 400-bed hospital experienced a non-room revenue 
increase of $2.27 per-patient-day attributable only 
to the capture of lost charges (The Data Communications 
User, 9).  At a conservative 70% average occupancy, 
this savings represents an increased yearly revenue in 
excess of $225,000.  Since the major areas where lost 
charges occur are pharmacy items (medications, dressings, 
etc.), laboratory testing, and centrally supplied 
patient items (syringes, dressings, etc.), pharmacy- 
related lost charges recovered by a CPS can be 
significant. 
A CPS can assist the pharmacist with medi- 
cation monitoring.  Before filling a prescription, the 
pharmacist uses a drug profile for each hospital in- 
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patient to identify possible interactions between the 
prescription and patient allergies and drug history-- 
medication monitoring.  As drug-order volume and 
hospital formularies ( the drugs Stocked by the pharmacy) 
increase, medication monitoring becomes more burden- 
some and the potential for undesirable drug-interactions 
can neutralize chemotherapy or cause harmful side- 
effects.  Medication monitoring can benefit from 
computer techniques because it requires repetitive 
table look-up and data correlation.  However, unlike 
inventory, narcotics control, and lost charges, which 
can be handled with business-system computer tech- 
niques, medication monitoring requires unique system 
processing and data base developments, since no 
parallel process exists widely outside the health- 
care industry. 
C.   Medication Monitoring - Drug Information 
Medication monitoring is becoming increasingly 
difficult.  The pharmacist, trained in the uses, 
effects, and interactions of drugs, must ensure that 
Dedication orders are within acceptable bounds of 
dosage, frequency, and patient limitations (allergies, 
etc.).  In addition, the pharmacist must maintain an 
overview of the patient's drug therapy to prevent drug 
11 
administration contraindicated by overall chemotherapy, 
patient sensitivites, or lab testing.  The pharmacy, 
the centra/l site for drug release, and staffed by person- 
nel trained in drug-utilization, is the logical place to 
perform medication monitoring.  However, the dynamic 
nature and large volume of drug information, such as 
intended therapy, dosage, frequency, contraindications, 
etc., that the pharmacist must use makes it difficult to 
perform the task accurately, and with current information. 
Some form of computerized drug information system that 
can store and retrieve drug-data may be used to aid the 
pharmacist perform medication monitoring. 
Drug information required for medication 
monitoring can help the prescribing physician, in 
addition to tMe hospital pharmacist.  To utilize 
chemotherapy, the physician must determine the proper 
drug, dosage, and frequency.  With the number of drugs 
available, this is a formidable task, and will become 
worse as more drugs are certified for use.  Also, the 
increased use of chemotherapy as a means of treatment 
increases the probability of some form of drug inter- 
action.  Cluff (10) points out that fear of adverse drug 
M_,   reactions is the major reason that physicians avoid many 
it drugs.  Timely drug information can aid the physician 
12 
to achieve maximum, but safe results from chemotherapy. 
A Drug Information Module linked to a 
Computerised Pharmacy Subsystem can assist the pharmacists 
with medication monitoring and the physicians with drug 
information.  To do so, the DIM must access a data base 
that contains utilization information for all drugs in 
the hospital formulary, and all in-patient drug pro- 
files.  In addition, the DIM should 
• identify potential interactions between drug 
orders. 
• identify potential interactions between a drug 
order and a patient drug-allergy profile. 
• indicate the nature and severity of potential 
drug interactions. 
• provide general information about a drug— 
uses, dosages, etc. 
• provide technical references. 
These capabilities would assist both pharmacists and 
physicians to make drug-usage decisions quickly and 
accurately. 
D.   Allentown-Sacred Heart Hospital Computer Center 
The ASH Computer Center, a non-profit EDP 
organization, services four hospitals: Allentown General, ' 
13 
Sacred Heart, Muhlenberg Medical Center, and the ASH 
Hospital.  The Center provides administrative EOP 
functions'such as patient billing, accounts receivable, 
general ledger, and payroll with batch operation.  On-line 
systems include patient registration, admission-transfer- 
discharge, patient information, patient locator, and 
charge collection, and are accessed from real-time 
terminals at numerous hospital locations.  The Center 
is presently developing a total HIS for each member 
institution.  To satisfy each hospital's needs and 
efficiently utilize Computer Center resources, each 
HIS Subsystem will be developed as a basic unit in one 
hospital, and applied with modifications in the others. 
HIS development has begun with a Physician 
Order Entry System (OES). The OES will capture physician 
orders as close as possible to the origination point, 
to minimize manual interaction and increase the 
efficiency and accuracy of handling and processing the 
data.  Since a major physician-order component is a 
medication request, and as previously stated, the pharm- 
acy is felt to be a high return computer-application 
area, the Pharmacy Subsystem is one of the initial 
Subsystems to be developed.  The ASH Hospital has been 
chosen for the development site of the pilot Pharmacy 
Subsystem. 
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CHAPTER 2 
CURRENT APPROACHES TO DRUG INFORMATION SYSTEMS 
The B-D SPEAR Pharmacy Subsystem 830 and the 
MEDITECH Pharmacy Subsystem are two major commercial 
information system efforts that represent current 
approaches to Computerized Pharmacy Subsystems.  Doth 
Subsystems offer drug-interaction monitoring during 
Medication order Entry, and the MEDITECH Subsystem 
also offers drug-information capabilities. 
A.   The B-D SPEAR Pharmacy Subsystem 830/MEDIPHOR 
Data Base. 
The B-D SPEAR Pharmacy Subsystem 830 is 
currently available as an add-on, real-time, interactive 
system for a hospital business mainframe, and provides 
a range of pharmacy-related functions that includes 
Medication Order Entry in the pharmacy.  Medication 
Orders are entered on cathode-ray terminals directly 
by formulary code, or indirectly, through a menu- 
selection process that leads the user through the data- 
entry procedure, and are their screened for potential 
interactions by the Subsystem.  Automatic audible and 
visual warnings are provided upon Order entry for 
duplicate Orders, known drug allergies, or potential 
15 
interactions with previously ordered medications.  If a 
drug-interaction is detected, the operator may request 
a report giving specific interaction information, 
and cancel the order, or override the warning.  To 
accomplish automatic Medication Order monitoring, the 
Subsystem 830 uses the MEDIPHOR Data Bas6. 
The MEDIPHOR Data Base is a computerized 
drug-drug interaction data base that was developed at 
the Stanford University School of Medicine.  MEDIPHOR 
is designed for real-time application to aid the 
physician and the pharmacist in health care delivery, 
and contains only thoroughly documented drug-interaction 
information.  For any drug-drug interaction in the data 
base, MEDIPHOR can provide.- 
• pharmacological effects of the interaction. 
• mechanism of the interaction. 
• clinical findings that might result from 
administration of the combination. 
• clinical significance of the interaction. 
• coded designation of the immediacy and severity 
of the potential consequences. 
• duration. 
• clinical management suggestions. 
• primary literature references for documentation. 
16 
To identify the urgency of a potential drug- 
interaction, MEDIPHOR uses an Immediacy Code to indicate 
the rate, bnd a Severity Code to indicate the net effect: 
Immediacy Codes 
(1) If the consequences of this interaction occur, 
they may be evident soon after the adminis- 
tration of this drug combination and (see 
severity codes). 
(2) If the consequences of this interaction occur, 
they may be evident after several doses of the 
drug combination are administered and (see 
severity codes). 
(3) If the consequences of this interaction occur 
they may not be evident until this drug 
combination has been administered for a 
variable period of time, but the (see severity 
codes) . 
(7) Same as code (3) except "but they" replaced with 
"but they may be ignored if one of the drugs is 
administered PRN" (as needed) (see severity 
codes). 
(4) Potential interaction, but not well documented, 
or thought to be not clinically relevant (see 
severity codes). 
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Severity Codes 
(1) May be potentially life-threatening or causo 
permanent damage. 
(2) May lead directly to deterioration of the 
patient's clinical condition. 
(3) May potentially lead to symptoms of toxicity 
or loss of therapeutic efficacy of one or both 
of the drugs listed in this report. 
(0) Undetermined. 
The Immediacy and Severity Codes are prominantly dis- 
played at the beginning of the drug-drug interaction 
report produced by the system. 
Sample System 830 output (Figs. 2.1 and 2.2) 
shows the result of a request for an interactive check 
between Coumadin and Percodan, both registered trade- 
names.  Coumadin, crystalline Sodium-Warfarine, is an 
anticoagulant used to prevent venous .blood-clotting. 
Percodan contains Oxycodone Hydrochloride, Aspirin, 
Phenacetin, and Caffeine, and is used to kill pain and 
sedate.  The System indicates two potential interactions 
between Coumadin and Percodan, based on their drug- 
ingredient Families. Warfarin is a Coumarin Anticoagu- 
lant, Aspirin is a Salicylate, and Phenacetin is an 
Acetaminophen Derivative.  Figure 2.1 details the poten- 
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rlguro 2.1 
Sample System 830 Output 
COM»llTI     IMftlNC t ion   HfO»l 
UH|.lMMf1.     MM... "il',-» 
1ELE»Mt)'it        ■«!.'"•    «•••-■**■»« 
IMKbtMC ri UVEPITu 
t>FVG  CGunHMM 
WITH rocot*>< 
DM»I       U*CFH?IH 
CLrtiii      CIX.»1»"<PItl  M'«I ICDMC.jtMfO : 
. t*Vii n,„F>tlMI< 
CLrtSil :M.kai*ii: 
r-Mn*t«.coLO<5Jc^L CFFC(T:I  PM^TIMIOLOOKAL irrtci: OF CO\«*DIM inc»t*:«i>. 
MECM^'I:«.I t.DitrnvE»: IH«- FT.:.in.. »«IOI T I E »*».»n.*.-oiO';iCAL FWTIVITV. 
lnr*l*MtrU   (V   rxr-ttLET   Ft.<i«. uon. 
CUMlCrH.   F|nM'«wii   KJlllllE   ItfEMIf-. 
cxinicm.  :iw<incr*«:n F»-OI**H.> 
EFFECT: «»t W3.t-i-t»ir«i-rin. 
U-MIFICHKT   tvl   r<lED*.  m>t 
r 1 
CLIMICI*.   MMiiMitHtnl      ■ AV-E '. t I Oil. I   rtHi   i«£CI*  LGUEF    tOIE   OF   (RUNtlN   P»-* I t«G 
C0fH"U**Ell!   Ht*1|!ll    IFHIIOM   OF   FtFCDI**!. 
FtFEF-El*.E:i 
«Mi:oii>P.n.   I   HEF*.0ii.F-.i«. ■ >. •   C I«(.«LAI IOM-i-«i   • l}'l**l" 
HErtf'.o.o.  •  MI>-.«»I'.I . i  FFtK   :DC E *> not. «r &•*?■<:••• !•»■•)• 
O'FCILLV.F.«. •   ET   H«..I    BIIH.'I,   M«.HI.   :ci«    l??i    I ."i-!»."!» 
D 
COMMENT; i I 
SHLICLHIE:  III *I.VM IO:E: *«>* 10 ►*.-■? Ft N^OF^OTM^OMI ucnic 
EFFECT   TIMILFrf    ID   1M*T    :Ell'  W|TM  CDUnjWIM  i*«T K0*'>«.MIT : . — 
CXIMICMULI   .lo-iu iiw»ii  r-ifiuvt  EFFECT: MMvt  UEM ci:t*-tr 
IN ;owt" F-*UEIH:.  IK*MIFKtii' OF Fv*TEi.t.T rL«<Ticti 1. ; 
SAUCVLHTC:    •! .iTPI   :CI'H»i   :mk.l"l£'   M*c *.'0 El****!   THE] 
F-OJilklLM.   OF   ILEEIIKV   IEMIEI*..    !•«  i^H KOFwXXFiTtli  FFlTllhT:. 
— I 
p I I—I 
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Figure  2.2 
Sample  System  8 30  Output 
COHM.ETE    IHHfM. TIOM  HPO»l 
^I0'7* 
WHLTM**.     IIM'.. ",>l^4 
If-LffHOftt •». I*>     .)yu-490(' 
nr~i 
IhnfDI^C.i '.-> JtVEPlTYi <l> 
t>F-uG  COUMrtMN 
WITH  fttrCOt'Hfi 
D»t»i        UMffftflll 
CL«:;i       COUTlM'Itl   AflTICDntVAHHT'. 
DFUvi F-MENACETIN 
CLASS l      ACETAflinCtf«EN   I'fUVHTlVt: 
F-NAKnACClLOOKriL   IFFECKI   I-MMHIAT OL DO IC ML   EFFECT:   OF   COUnAb 
HCCMAMI;M:I CH» I<CN»<. 
CLINICAL   FlNP|HC.;i   t-CtUClIi   F-*OTHftt)H»IN  LEVELS.   POT! I »LE   ILE 
« 
CLINICAL   JIG»l|F|CANCEi   F10!"ILY   J VWUF ICA»IT   H/T   NEED:   nO»C   i TKtrC 
EFFECTS   Htfc   bCKE-MFEHltiiT. I 
7^ 
it> ir*(E<uet>. 
r 
CLINICAL   "**<*..£ HINT   'lrts>f : TIOn:i   n*r   ItEFt-  LOUCP   DO'.E   OF   COunADIN   Dl* |NO 
COMCUF^EK?   HIITINISTPHT |QN  UF   FLFCOWtfl. I < 
F-CFL«.f«CE:i I       I     I       I 
AMlLlir.A.f.. .   El   ML. I   tl*F   TMEP   »tS>    101    50l-l«*«i 
W1TLI 12.A.M.   t   HUMLT.L.F.I   CVH>   THE*  F-E:.    Ill   UOHNV 
UPHLL-J.M.I   <if.   401    ll.'.|*t>9) 
COMMENTS • 
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tial interaction of a Coumarin Anticoagulant with a 
Salicylate, and indicates an Immediacy Code of (3) and 
a Severity Code of (1)— if the consequences of this inter- 
action occur, they may be evidont after several doses 
of the drug combination are administered, and may be 
potentially life-threatening or cause permanent damage. 
Additional data indicates the probable interaction 
cause, corrective drug-management and technical refer- 
ences.  Figure 2.2 is a report of the potential inter- 
action between Coumarin Anticoagulants and the Aceta- 
minophen Derivative, Phenacetin, also present in Per- 
codan. 
The System 830 reports indicate that a drug- 
ingredient Family comparison is used to identify poten- 
tial drug-interactions on Medication Orders.  It can- 
not be determined if higher level checks are made once 
a potential interaction is flagged— such as comparing 
the Acetaminophen Derivative Family against the Coumarin 
Anticoagulant Family, detecting a potential interaction, 
and then comparing Phenacetin against Karfarin for more 
specific interaction detail. 
B.   The MEDITECH Pharmacy Subsystem. 
The MEDITECH Pharmacy Subsystem currently under 
development is designed to directly interface with other 
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MEDITECH Subsystems— such as Billing and Accounts 
Receivable, and Census —and is dependent upon these 
subsystems for some data-processing.  For example, 
patients are initially entered into the Pharmacy Sub- 
system by the Hospital Admissions Office with the MEDI- 
TECH Census Subsystem.  Therefore, it would be im- 
practical to consider purchasing the MEDITECn Pharmacy 
Subsystem alone, or as an add-on subsystem. 
The MEDITECH Pharmacy Subsystem, like the Sub- 
system 830, will maintain a Medication Order and drug- 
allergy profile for all active in-patients.  Medication 
Orders will be entered via on-line terminal by a pharma- 
cist or technician, and will be automatically screened 
by the subsystem for potential drug-drug interaction, 
patient-allergy interactions, and when available, 
laboratory-drug interactions.  The Subsystem will not 
allow the entry of interactive medications without a 
deliberate override command by the terminal operator. 
Upon detection of a potential Medication-Order-inter- 
action, the Subsystem will print an interaction descrip- 
tion (no sample reports available at this time), and 
ask the operator for either an override or an Order 
cancellation. The operator must verify the Order pro- 
priety with the physician to determine the appropriate 
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action. 
There will be a MEDITECH Subsystem routine 
for interactive queries on potential drug-interactions 
that will offer three search options: 
• Drug-Drug. 
• Patient-Drug. 
• Laboratory-Drug. 
The Subsystem will accept requests for interaction 
checks using specific medications, or general drug- 
Families.  This indicates that the Subsystem will have 
the interaction-data necessary to perform a two-level 
interaction check— drug-Family, then specific drug —but 
it cannot be determined if this will be the operational 
mode for monitoring Medication Order entries.  The 
interaction reports returned by the routine will include 
associated textbook type entries that will elaborate 
upon the interaction effects. 
A Subsystem Interaction Dictionary, generated 
by the MEDITECH Corp., stores the data necessary to sup- 
port drug-interaction checks.  The four options available 
with each Dictionary Routine: 
• Enter Data 
• Edit Data 
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• Delete Data 
• List Data 
will allow selected pharmacy members to add to the basic 
drug-data from staff experience, and update the Inter- 
action Dictionary. 
C.   Pharmacy Subsystem Drug Interaction Summary. 
Since both the System 830 and the MEDITECH 
Subsystem are commercial developments, specific infor- 
mation on their design and operational methods is un- 
available.  However, for this study, it is sufficient 
to know the basic drug-interaction capabilities that each 
subsystem will provide, and indicate the interaction 
data base source.  A summary of this information is 
provided in Table 2.1. 
Aside from the absence of drug information 
routines in the Subsystem 830, the major subsystem 
difference is the interaction data base source.  The 
Subsystem 830 seems oriented towards providing a total 
Pharmacy Subsystem Package, and includes the MEDIPHOR 
Data Base.  The MEDITECH Subsystem, however, provides an 
initial Interaction Dictionary, and the routines to ex- 
pand and update the Dictionary.  This places the burden 
of keeping the interaction-data current on the pharmacy 
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staff, but results in a data base that nay be readily 
modified to meet the needs of a specific pharmacy. 
The choice of either data base approach involves a 
trade-off between minimal data maintenance or specially 
modified data, and must be applied to the pharmacy 
at hand— its needs and capabilities. 
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Table  2.1 
System Summary 
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CHAPTER 3 
DRUG INFORMATION MODULE - USER ANALYSIS 
This chapter examines the Drug Information 
Module's functional environment to identify: 
• the primary DIM users. 
• the user decision-processes and information req- 
uired to perform DIM-related tasks. 
A.  The Drug Information Module User. 
The primary DIM user should be defined as the 
staff pharmacist for three reasons: 
• contact — with the drug information process. 
• centrality — to all physicians. 
• controllability — in a constant work environment. 
The staff pharmacist is responsible for drug 
issue, based upon a Medication Order, and must utilize 
hie knowledge of drug management and available patient 
information to ensure Medication Order propriety. There- 
fore, every time that the staff pharmacist performs his 
primary function, drug issue, drug information analysis 
must be a major process step. The pharmacist must 
validate the drug, the dosage, and the medication manage- 
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ment while considering available patient information on 
concurrent drug therapy and allergies.  The pharmist's 
function may be viewed as a two-part process— drug 
information analysis, followed by the actual drug issue 
(to include such administrative activities as inventory 
and billing).  The utilization potential for a DIM by 
the staff pharmacist is clearly very high. 
At ASSH, the staff pharmacist is central to 
both the drug location and the information required to 
initiate drug usage, since all medications for in-patient 
treatment must come from the hospital pharmacy after 
review by a staff pharmacist.  If drug information 
analysis is utilized in this process, the capabilities 
of such a system are automatically passed on to all 
physicians in the hospital, as they order medications 
from the pharmacy. 
Finally, the staff pharmacist works in a 
constant job-environment (fixed staff and responsib- 
ilities) necessary for the development, implementation, 
and fine-tuning of a Drug Information Module.  The 
hospital pharmacy work-force can provide a stable nucleus 
of DIM users for design and feedback purposes.  After 
implementation, this same nucleus can provide DIM 
resident experts to attend to necessary user-maintenance. 
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Once the DIM is integrated into the pharmacy operation, 
the necessity for interaction with the DIM will ensure 
that new pharmacists become skilled in it's use— 
eliminating the problem of staff turnover in the DIM 
user group.  An additional benefit is that the staff 
pharmacist who must perform drug information analysis 
constantly can provide user-assistance to occasional 
DIM users such as physicians. 
For design consideration, the staff pharmacist 
is recommended as the primary DIM user. 
B.  Medication Order Process in the Pharmacy. 
The steps required to process a Medication 
Order into a drug delivery at the ASH Pharmacy are 
outlined in Fig. 3.1: 
1. The process is initiated by a Medication Order 
(see Fig. 3.2) that is written by the attending 
physician and submitted to the nursing station 
to which the patient is assigned.  The nursing 
station forwards a copy of the Medication Order 
to the pharmacy for drug issue. There is no 
other drug-related input to the pharmacy. 
2. The Medication Order is time stamped by a 
pharmacy technician as a control for the time 
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Pigure  3.1a 
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Figure 3.1b 
13) 
14) 
15) 
16) 
17) 
!•) 
YES DELIVER 
ORDER 
IMMEDIATELY 
POT ORDER 
IN 
CASSETTE 
DELIVER 
CASSETTES 
RETURN 
USED 
CASSETTES 
CALCULATE 
KEOS 
USED 
ENTER 
KEOS ON 
MOTILE 
^ r  
31 
Figure 3.2a 
Doctor's Order Sheet 
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Figure 3.2b 
Doctor's Order Sheet Entries - Refers to Pig. 3.2a 
 1  
1. Patient Identification from hospital-issued 
ID card. 
2. Known patient drug allergies from medical 
record or entrance interview. 
3. Doctor's Order written by attending physician 
who enters Date, Time, and the Order— which 
may be for medication, lab testing, etc. 
4. Initials of the patient's unit clerk who 
transcribes, if necessary, any Doctor's 
Orders onto appropriate hospital forms— such 
as lab test requests. 
5. The Time that the unit clerk transcribes the 
Doctor'8 Order. 
6. The patient's  Registered Nurse verifies 
any transcribed Doctor's Orders and enters 
the R.N. Signature if the transcription is 
accurate. 
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that it takes to actually issue the medication.  * 
3. The technician routes the Medication Order to 
the I.V. Room— where all intravenous solutions 
are formulated. 
4. The Order is reviewed for I.V. content. 
5. If an I.V. solution is required, the mixture is 
prepared in the I.V. Room. 
6. The I.V. solution-issue is entered on the I.V. 
Profile (see Fig. 3.3) . 
7. The Medication Order is then routed to the 
appropriate pharmacy work-station— the pharmacy 
is divided into four work-stations that are 
responsible for specific nursing stations. 
8. The pharmacist reviews the Medication Order and 
considers such factors as dosage, frequence, 
and concurrent patient medication as indicated 
on the Pharmacy Medication Profile (see Fig. 3.4) 
for each in-patient. 
9. If the pharmacist has reason to question any of 
the Medication Order parameters, he contacts the 
writing physician and indicates why he feels that 
the Order may be inappropriate.  If the writing 
physician cannot be located, the present physi- 
cian in charge is contacted. 
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Figure 3.3a 
Pharmacy I.V. Profile 
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Figure 3.3b 
I.V. Profile Entries - Refers to Fig. 3.3a 
1. Patient I.D. data. 
2. Any special patient data that may affect I.V. 
formulation. 
3. Patient physical data used to check strength 
of requested I.V. solution. 
4. Known patient allergies or drug sensitivities. 
5. Patient diagnosis, if available. 
6. Initials of pharmacist mixing I.V. solution. 
7. Basic solution plus drugs added to formulate 
the I.V. solution. 
8. I.V. solution bottle-volume. 
9. Frequency I.V. solution is to be administered. 
10. Manufacturer'8 No. and Expiration Date of 
basic solution used to formulate I.V. solution. 
11. How fast the I.V. solution is to be 
administered. 
12. What I.V. solution has been ordered. 
13. What I.V. solution has been prepared. 
14. What I.V. solution has been sent to the 
patient's unit. 
15. I.V. solution computer-identification code. 
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Figure 3.3b continued 
16. Total I.V. solution units used by patient 
after any returned I.V. solutions are received. 
17. Unit I.V. solution price. 
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Plguro 3.4a 
Pharmacy Medication Profile 
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Figure 3.4b 
Medication Profile Entries - Refers to Fig. 3.4a 
1. Patient I.D. data. 
2. Known patient allergies or drug sensitivities. 
3. Medication requested by physician on Doctor's 
Order. 
4. Drug dosage from Medication Order. 
5. Frequency of drug administration from Medication 
Order. 
6. Route of drug administration from Medication 
Order. 
7. Drug dosage sent. 
8. Date and description of drug sent. 
9. Amount of drug used after returned drug 
cassettes are inventoried for returned Sent 
Dosages. 
10. Drug Computer-I.D. Code. 
11. Total Drug Units used by patient. 
12. Total Cost of drug used by patient. 
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10. If indicated by either physician, the pharmacist 
will modify the Medication Order to correct the 
parameter in question. 
11. The pharmacist fills the Medication Order with 
drugs from pharmacy stock. 
12. The pharmacist updates the patient's Medication 
Profile with the: 
a. drug identifier. 
b. dosage. 
c. frequency. 
d. route of administration. 
e. sent dose. 
f. date. 
g. amount sent. 
13. If the Medication Order is a stat (emergency) 
initial, or transfer order, the medications are 
sent to the nursing station as soon as the Order 
is processed (these Order types are required 
immediately, and are for one dose only). 
14. Otherwise, the medications are put in a cassette 
identified by patient name, and loaded into the 
appropriate nursing station cart. 
15. The cassettes containing the medications are 
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delivered to the nursing stations daily at 3 p.m. 
16. The cassettes from the previous day are returned 
to the pharmacy. 
17. By inventorying returned medications, the pharma- 
cist calculates the amount of issued medication 
actually used by the patient. 
18. The pharmacist enters the medications used on the 
patient's Medication Profile.  Note that stat, 
initial and transfer medications are one dosage 
only, and require no medications-used calcula- 
tions . 
These steps accomplish the verification, issue, and docu- 
mentation of all Medication Orders that are presented to 
the ASH pharmacy. 
C.  DIM-Related Medication Order Processes. 
To ensure accurate discussion of pharmacy drug- 
procedures, a classification hierarchy was defined and 
used with the ASH Hospital pharmacy staff— the sample 
shown represents aspirin: 
• CLASS - Analgesic (Pain Killer). 
• FAMILY - Salicylate (Form of Salicylic Acid). 
• GENERIC - Aspirin (General Chemical Name). 
• BRAND - Bayer, etc. (Brandname). 
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The Information used by the pharmacist to 
review a Medication Order is contained on the Pharmacy 
Medication Profile (Pig. 3.4).  This form is initiated 
for each in-patient and represents the patient drug- 
profile for ten days.  In addition, patient allergies, or 
special conditionc are noted in entry no. 2.  The pharma- 
cist compares each new Medication Order to the existing 
medication/dosages and allergy notes and if no conflicts 
appear, the new drug is issued, and entered onto the 
Medication Profile.  Two main purposes for the review  / 
are to detect: 
• direct allergic/cross-sensitivity reactions. 
• drug-drug interactions. 
A direct allergic reaction occurs when a drug that 
contains an ingredient to which a patient has an allergy 
is administered, and causes a hyper-sensitive reaction 
in the patient.  A cross-sensitivity reaction is an 
allergic reaction that occurs when a patient is given a 
drug that has a chemical structure very similar to some 
drug for which the patient has a known allergic reaction. 
It is possible that the difference in the drugs' chemical 
structure will be small enough to be transparent to the 
allergy mechanism, and that a hyper-sensitive reaction 
42 
will bo triggered.  This is particularly true when the 
two drugs are in the same drug-Family, since the Family 
classification defines a drug group of similar major 
chemical composition. 
A drug-drug interaction occurs when a drug's 
mechanism of operation interacts with that of a second 
drug, with a net result of either an increase or decrease 
in the effective blood-levels of one of the interactive 
drugs.  If simultaneous drug administration is valid, it 
is necessary to adjust the normal dosages for one, or 
both, of the drugs.  Since the drug-Family implies a par- 
ticular chemical composition, and therefore a probable 
mechanism of operation, a check for potential drug-drug 
interactions may be done on the drug-Family identifier. 
Both the direct allergic/cross sensitivity reaction and 
the drug-drug interaction checks on the drug-Family are 
complicated by the fact that a particular Generic or 
Tradename may represent a drug that contains multiple 
ingredients of more than one drug-Family.  This was seen 
in Chapter 2, Example 1, where one drug Tradename, 
Percodan, was shown to contain ingredients of four drug- 
Families: 
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Percodan Ingredient        Drug Family 
Oxycodone Hydrochloride Opium Derivative 
Aspirin Salicylate 
Phenacetin Acetaminophen Derivative 
Caffeine Xanthine Alkaloid Derivative 
The overall review process, represented by 
Fig. 3.5 that is accomplished by the pharmacist includes: 
1. The Medication Order drug is converted from the 
Generic or Tradename to a drug-Family profile 
that represents all of the drug's ingredients. 
2. The drugs from the Medication Profile that the 
pharmacist wishes to compare against the Medica- 
tion Order— either concurrent medications or 
known allergies— are converted to a drug-history 
Family profile. 
3. For a direct allergic/cross-sensitivity reaction, 
the pharmacist searches for a match between any 
drug-Family elements of the two profiles that 
would indicate a potential hyper-sensitive re- 
action if the drug were administered.  For a 
drug-drug interaction, the pharmacist uses the 
elements of both profiles, creates all possible 
drug-Family pairs, and searches for a pair known 
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Figure  3.5a 
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to be potentially interactive. 
In both cases, when a potential drug interaction is 
detected, the pharmacist applies knowledge of the sever- 
ity and probability of the event to determine if the 
Medication Order should be verified with the writing 
physician.  If this is the case, the pharmacist will hold \ 
the Order and notify the physician of the potentially 
interactive parameters.  The physician retains final 
control over Medication Order modification. 
An important observation is that each check— 
the direct allergy/cross-sensitivity reaction and the 
drug-drug interaction— performed by the pharmacist 
involves converting all drug-identifiers to corresponding 
drug-Family identifiers.  This indicates that this is the 
drug-identifier level that the DIM should utilize to 
simulate the Medication Order validation process. 
D.   Drug Information Required for the DIM. 
To provide drug information to the staff 
pharmacist, the DIM must access— for each drug in the 
hospital formulary— the: 
• drug Generic or Tradename. 
• drug-Families of ingredients. 
• drug-interaction data. 
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• drug-management data. 
The ability to recognize a drug by either the Generic 
or Tradenane is necessary, since the physician may use 
either form when a Medication Order is written, and since 
the Medication Order must be entered on the Medication 
Profile as issued, the Profile will contain either Gen- 
eric or Tradenames. 
Once a drug has been identified by either the 
Generic or Tradename, it must be possible to create a 
drug-Family profile of the ingredients, since this is the 
basis used to compare the Medication Order against the 
patient's Medication Profile.  Concurrently, the Medica- 
tion Profile must be converted to a drug-history Family 
profile for the process— which again requires a correla- 
tion between the drug Generic or Tradename and the 
related drug-Families. 
To verify a Medication Order against a drug- 
history Family profile, a Family - Family search keyed 
on any patient drug allergy will indicate direct allergy 
and potential cross-sensitivity reactions,  nowever, to 
detect a potential drug-drug interaction, interactive 
drug-Families must be available for each possible drug- 
Family pair created with the formulary drugs, along with 
specific interaction-data to indicate: 
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• The potential results of the indicated drug- 
Family interaction, in addition to BOOM indication 
of the interaction probability and severity. 
• The mechanism of the potential interaction, and 
the mechanism's clinical significance. 
> 
• Drug management indicated by the interaction 
mechanism. 
• Technical references to support all information 
previously stated. 
Access to this information will allow the DIM 
to simulate the staff pharmacist's medication monitoring. 
In addition, normal drug management data may be added to 
expand the usefulness of the DIM to the physician for 
pre-prescription drug information assistance.  This might 
include drug data such as: 
• Usage— positive clinical effects obtained from 
drug use, with criteria to indicate when the drug 
should be avoided. 
• Regimen— suggested standards of dosage and fre- 
quency by age and weight. 
• Packaging— method and quantity of dispensing the 
drug most suitable to pharmacy operation, and any 
such pertinent information. 
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Drug-record layouts should be designed so that this 
information may be added at an appropriate implementation 
stage. 
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CHAPTER 4 
THE DRUG-INTERACTION/INFORMATION DATA BASE 
*•  Information Category. 
As indicated in Chapter 3, to assist the staff 
pharmacist compare and validate a Medication Order 
against the appropriate in-patient Pharmacy Medication 
Profile, the DIM requires access to a drug data base that 
contains: 
• the ingredients and respective drug-Families of 
all formulary drugs. 
• drug-pairs that may have harmful effects if both 
drugs are administered simultaneously. 
• technical information on the drug-pair interaction 
mechanism. 
• recommended drug-management to minimize the poten- 
tial drug-interaction if simultaneous application 
of both drugs is still desired. 
• textbook references for the drug-interaction. 
In addition, to assist the physician choose the most 
appropriate drug and administration parameters for a par- 
ticular application, the DIM must have access to drug 
information such as: 
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• technical drug use. 
• standard dosage. 
• standard application-frequency. 
• administration route. 
• special application parameters. 
Since a literature search indicates no vendor of drug 
data bases specifically designed to match a particular 
pharmacy's formulary Generic content and available 
dosages, it will be necessary for the ASH Computer Center 
to construct such a data base.  There are three logical 
subsets of this drug data base— the formulary subset, 
the drug-interaction subset, and the drug information 
subset— that must be defined for design purposes. 
B.   Formulary Subset. 
The formulary subset must contain all ASH 
formulary drugs, their associated ingredients, and ingre- 
dient drug-Families.  The basis for this subset is the 
current formulary, a manually maintained list of all 
drugs and application parameters, identified by both 
Generic and Tradename, that are stocked by the pharmacy. 
The formulary is reviewed and updated by a Pharmacy and 
Therapeutics Committee (PTC), under authority of the 
hospital Medical Staff Executive Committee.  All 
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formulary changes require PTC approval. 
Since ASH purchases drugs on yearly bids— 
and a formulary drug Tradename will change with the 
pharmaceutical source— the formulary Tradename content 
may experience a high yearly turnover.  However, the 
formulary Generic content will remain fairly constant. 
This variance may be resolved by use of a drug code 
number, uniquely defined for each drug, as a primary 
drug identifier and the Generic and Tradenames as 
secondary and tertiary drug identifiers. 
To generate the formulary subset, a review 
group of pharmacy management and professional staff must 
sequentially examine all formulary elements to determine 
the active ingredients and classify the ingredient drug- 
Families.  For each formulary drug, the group should 
define the: 
• drug code I. 
• Generic Name. 
• current Tradename active ingredients. 
• ingredient drug-Families. 
and have this drug data approved by the PCT.  The 
approved version of this formulary data must then be 
coded and made machine-readable to create the formulary 
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subset. 
C.   Drug-Interaction Subset. 
There are two alternatives that may be used to 
generate a drug-interaction subset for the DIM data base. 
The first would be to utilize a widely established hand- 
handbook of drug-interactions such as Hanston's Drug 
Interactions (11) that contains a thorough drug-inter- 
action tabulation for most drugs licensed for use by the 
Federal Drug Administration.  This handbook is designed 
for use as a pharmacy drug-application reference, and 
contains interaction information on both individual drug 
and drug-Family levels.  Since the handbook can provide 
all the drug parameters for the drug-interaction subset, 
it would be possible to manually generate all drug-pairs 
of interest, and then reference the associated interac- 
tion data from the handbook.  However, since this would 
be a tedious process, and would require successive itera- 
tions to maintain subset currency, it should be avoided 
if possible. 
The second alternative would be to purchase a 
commercial, interactive drug-pair data base with associa- 
ted interaction data. There are three such data bases 
that have been developed with high professional standards 
and are suitable for general application: 
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• the Stanford University Mcdiphor Data Base. 
• the University of Missouri Drug-Interaction Data 
i 
Base. 
• The University of South Carolina (USC) Drug- 
Interaction Data Base. 
All three of these data bases contain the required inter- 
action data for the DIM application.  However,-the Medi- 
phor Data Base has been licensed for use in the B-D Spear 
Corporation Computerized Pharmacy Subsystem commercial 
package, and is not available separately.  In addition, 
the University of Missouri Data Base was purchased by the 
Baxter Pharmaceutical Corporation for commercial package 
development and is currently unavailable. 
The commercial rights to the USC Data Base have 
been licensed to the Bell & Howell Corp., which functions 
as a wholesaler, and distributes the data base in 
microfiche form to major drug companies, such as 
McKessen Pharmaceutical Corp., which retail the data base. 
The USC Data Base contains all significant interactive 
drug-pairs cited in Hanston's Drug Interactions on both 
Generic and Family levels.  Linked to each drug-pair is: 
• the potential drug-interaction effects. 
• the probable drug-interaction mechanism. 
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• drug-management techniques to minimize the inter- 
action effects if the drug-pair must be adminis- 
tered. 
• the rate and severity of the potential drug-inter- 
action in a danger-level code. 
• technical references that document the interaction 
data. 
and update microfiche for this information are available 
biannually.  For these reasons, the USC Data Base is 
recommended as the DIM drug-interaction subset source. 
D.   Drug-Interaction Subset Source Conversion. 
The USC Data Base contains approximately 10,000 
interactive drug-pairs with associated interaction infor- 
mation.  Since the ASII pharmacy can only dispense formu- 
lary-drugs, any data not formulary-related is extraneous, 
and should not be included in the subset.  Both elements 
of the drug-pairs required for the DIM data base must 
also be members at the ASH formulary, for there should 
be no interaction-data need if either of a drug-pair is 
unavailable from the pharmacy.  This check must be on a 
Generic basis, since the formulary only contains one of 
several possible Tradenames for a particular Generic 
drug. 
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Khen the appropriate drug-pairs for DIM opera- 
tion have been extracted from the initial data base, it 
will be necessary to review the linked interaction infor- 
mation for possible modification to ensure that it is 
compatible with ASH pharmacy procedures and professional 
philosophy.  This may be accomplished by the previously 
defined review group, and again, subject to PCT approval. 
To assist with these two major conversion tasks: 
• an efficient means to identify formulary-related 
drug-pairs in the initial data baso is necessary. 
• a method to modify the interaction information 
linked to a drug-pair is required. 
Since the USC Data Base is currently available only in 
microfiche form, the applicable content must eventually 
be coded and made machine-readable. A procedure to 
accomplish this task efficiently is: 
1. Code only the Generic-Family drug-pairs (no 
interaction data) from the initial drug- 
interaction data base. 
2. Utilize a production program to identify the 
drug-pairs that have a two-element match with the 
formulary subset members— the applicable residue 
of the initial data base —store excess drug-pairs 
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for future formulary modification. 
3. Convert the Generic elements of the drug-pairs to 
the appropriate drug code numbers. 
4. Code and make machine-readable the interaction 
information linked to the drrug-pair residue— 
this creates the drug-interaction subset. 
5. Produce a subset report for review by the pharma- 
cy group and the PCT. 
6. Utilize a production program to access and modify 
the subset as indicated by the review group(s). 
This procedure requires that the formulary subset be 
completed for use as a drug directory to convert the 
Generic names to drug code numbers.  It will generate the 
drug-interaction subset, and may be used in the same 
order on a smaller scale to process the subset updates. 
E.   Drug-Information Subset. 
The DIM data base drug-information subset must 
contain: 
• technical drug use 
• standard application-frequency 
• administration route 
• special application parameters 
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To construct the drug-information subset, a nationally 
recognized drug reference, Facts and Comparisons (12) may 
be used.  For all commercial drug products currently 
available from established pharmaceutical firms, Facts 
and Comparisons references by both drug Generic and 
Tradename: 
• chemical derivation 
• action mechanism 
• special application parameters 
• technical use 
• standard dosage 
• standard application-frequency 
• administration route 
and update issues are available monthly. 
Since Facts and Comparisons is widely recog- 
nized by health-care professionals as a drug-information 
standard and contains the information the DIM operation 
requires, it is recommended as the drug-information 
subset source. 
F.  Drug-Information Subset Source Conversion. 
Only drug-information that pertains to the ASH 
formulary is required from Facts and Comparisons, the 
drug-information subset source. To convert the source 
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data to a DIM-suitable form, a procedure similar to that 
defined for the drug-interaction subset will be necessary. 
Since the source data is not currently available in 
machine-readable form, the recommended conversion proce- 
dure is: 
1. Utilize an ASH formulary Generic-printout to 
identify the drugs that must be extracted from 
the source data. 
2. Extract and make machine-readable the drug- 
information specified in Section 4.C— with the 
drug code number as the primary identifier —to 
create the initial drug information subset. 
3. Produce a subset report for review by the pharma- 
cy group and the PCT. 
4. Utilize a production program to access and modify 
the subset as indicated by the review group(s). 
This procedure will generate the drug-information subset, 
and again, may be used to process the subset updates. 
G.   DIM Data Base Organization. 
The three subsets, properly linked, will form 
the DIM data base. Entrance into the data base must be 
possible by either: 
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• drug code number 
• Generic Name 
• Tradename 
and once the data base is entered, the contents of all 
three subsets must be equally available.  Since each 
formulary drug has been assigned a unique drug code 
number, and the formulary subset is accessible by drug 
code number, Generic Name, or Tradename, it is logical 
to organize each data base subset by drug code number, 
and to enter the data base through the formulary subset 
as indicated in Fig. 4.1: 
Figure 4.1 
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8ince this organization will eliminate redundant storage 
of drug Generic or Tradenanes and provide the most direct 
access to all data from the entry point, it is recom- 
mended as the overall structure for the DIM data base. 
^ 
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CnAPTCP 5 
DRUG INFORMATION MODULE DESIGN SPECIFICATIONS 
This chapter consolidates the DIM criterion 
previously defined into design specifications that 
include: 
• an overall DIM flowchart to indicate the relation- 
ships between the required processes and input/ 
output data. 
• a suggested DIM data base schema. 
• design assumptions. 
• implementation constraints. 
• controls 
• back-up 
• major conversion and implementation tasks. 
A.    DIM Flowchart - Figure 5.1 
Step 1:  The DIM accepts a process request 
from the Pharmacy Subsystem.  The request may be either 
of two types: 
1. A new Medication Order request that has been 
obtained from the Pharmacy Subsystem Medication 
Order file that contains all Orders entered into 
the Subsystem.  The request contains: 
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Figure 5.1a 
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Figure 5.1c 
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a. Patient Identification. 
b. Drug Ordered (only one) . 
c. Date and Time Ordered. 
d. Writing Physician Identification. 
2. A drug information request that has entered the 
Pharmacy Subsystem from an on-line source to 
which the response will be routed.  The request 
consists only of a drug identifier: 
a. the drug code number, or 
b. the Generic Name, or 
c. the current formulary Tradename. 
Step 2:  The DIM determines whether the 
request is a Medication Order or drug information 
request and routes the process to the appropriate DIM 
section. 
Step 3;  The request has been determined to be 
a new Medication Order, and the object patient is iden- 
tified. 
Step 4; The object patient's medication record 
is obtained from the Pharmacy Subsystem patient medica- 
tion file that contains drug data on all current 
in-patients.  The medication record contains: 
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1. patient drug allergies. 
2. medications pharmacy-issued to the patient for 
the past ten days: 
a. drug Generic or Tradename. 
b. dose. 
c. frequency. 
d. alministration route. 
Step 5:  The drug allerqies from the patient 
medication record are converted into Profile A, that 
contains all drug-Families represented by the active 
ingredients of the known allergic drugs.  The necessary 
drug information is obtained from the DIM drug data 
base: 
1. drug identifier. 
2. active ingredients. 
3. active ingredient drug-Families. 
Step 6:  The current patient medications are 
converted into Profile B in a procedure parallel to 
Step 5. 
Step 7; The Medication Order drug is con- 
verted to a drug-Family profile (DFP) in a procedure 
parallel to Step S. 
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Step 8:  The DIM searches for a match between 
any member of Profile A (allergios) and the DPP (Medica- 
tion Order). 
Step 9;  If a match is identified in the pre- 
ceding step, a potential allergic reaction has been 
identified and the DIM stores for future use: 
1. Medication Order drug. 
2. reactive ingredient. 
3. reactive ingredient drug-Family. 
4. patient allergy drug. 
Step 10:  The DIM creates a drug-Family pair 
with the first Profile B (current medications) member 
and the first DFP (Medication Order) member. 
Step 11:  The DIM Drug Data Base is searched 
for the pair created in Step 10. 
Step 12:  If the pair is located in the data 
base, a potential drug interaction has been identified. 
The associated interaction data is obtained from the 
data base: 
1. potential interaction severity. 
2. suggested interaction mechanism. 
3. drug-management techniques for concurrent appli- 
cation of both drugs. 
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4. technical references to document the interaction. 
Step 13:  The next member of Profile B (current 
medications) is paired with the current DFP (Medication 
Order) member, and the DIM returns to Step 11 to search 
the DIM data base on the new pair.  The process continues 
until all Profile B members have been paired with the 
current DFP member. 
Step 14:  The next DFP member is paired with 
the first Profile B member and the DIM returns to Step 11 
as above.  The process will then continue until all DFP 
(Medication Order) members have been sequentially paired 
with all Profile B (current medication members) and the 
DIM data base searched.  This exhausts all possible 
combinations of the DFP and Profile B members. 
Step 15:  The validation process has been 
completed.  If a potential allergic reaction has been 
identified, the DIM passes to the Pharmacy Subsystem a 
report that contains: 
1. patient identification. 
2. potentially interactive Medication Order. 
3. interactive Medication Order ingredient. 
4. interactive ingredient drug-Family. 
5. interactive allergic drug note. 
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Step 16:  If a potential drug-drug interaction 
has been indicated, the DIM passes to the Pharmacy 
i 
Subsystem an interaction report that contains: 
1. patient identification. 
2. potentially interactive Medication Order. 
3. interactive current medication(s). 
4. potential interaction severity(ies). 
5. suggested interaction mechanism(s). 
6. drug-management techniques for concurrent drug 
application. 
7. technical references. 
Step 17:  The DIM returns to Step 1 to accept 
a new process request from the Pharmacy Subsystem. 
Step 18;  The process request has been identi- 
fied as Type 2, a drug information request.  The DIM 
Drug Data Base is searched on the request's drug identi- 
fier, and general drug information obtained: 
1. drug Generic Name. 
2. chemical derivation. 
3. technical use. 
4. mechanism. 
5. standard dose. 
6. standard application frequency. 
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7. administration route. 
8. special application parameters. 
i 
Step 19:  The DIM passes the general drug 
information report generated in Step 18 to the Pharmacy 
Subsystem. 
Step 20:  The DIM returns to Step 1 to accept 
a new process request from the Pharmacy Subsystem. 
B.   DIM Data Base Schema. 
The three data base subsets defined in 
Chapter 4: 
• formulary subset 
• drug interaction subset 
• drug information subset 
may be organized into record types and corresponding 
linkages as shown in Pig. 5.2, to create the DIM data 
base. 
The formulary subset contains five record 
types: 
1. CODE-REC:  Drug Code Number (data base key). 
2. NAMEl-REC:  Generic Name (data base key). 
3. NAME2-REC:  Current Tradename (data base key). 
4. INGRED-REC:  Drug ingredient. 
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Plgurc 5.2 
DIM Data Base Schema 
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5. INGRED-FAM-REC:  Ingredient drug-Family (data 
base key). 
i 
The 1:1 relationships between record types 1, 2, and 3 
form the data base entry point by either Drug Code 
Number, Generic Name, or current formulary Tradename, 
and allow conversion between the three types of drug 
identifier.  Once a particular Drug Code Number has been 
identified, the related drug ingredients, and their 
respective drug-Families are available for DIM use. 
The drug interaction subset contains the 
FAM-INTERACT-REC record type, which is accessed via the 
appropriate INGRED-FAM-REC formulary subset record. 
This subset contains a record occurrence for each drug- 
Family interactive with a particular INGRED-FAM-REC 
occurrence.  This allows an interactive drug-pair to be 
simply identified: 
1. Access the INGRED-FAM-REC occurrence of the first 
Family-pair member. 
2. Sequentially access all interactive FAM-INTERACT- 
REC occurrences linked to the INGRED-FAM-REC 
occurrence and compare the drug-Family field to 
the second Family-pair member. 
3. A match on drug-Families indicates that a 
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PAM-INTERACT-REC occurrence has been located 
from which the interactive data nay be accessed. 
i 
The drug information subset contains the 
INFO-REC record type, which is accessed via the appro- 
priate CODE-REC formulary subset record, and contains 
general drug information. 
In this form, the DIM data base can provide all 
information required for stated operation and stores no 
redundant data. In addition, this data base organization 
lends itself to tasks that involve the formulary content, 
such as printing the formulary, a task now done manually, 
or listing all formulary drugs and associated interactive 
formulary drugs; a task that is now impractical. 
C.   Design Assumptions. 
Certain assumptions have been made for initial 
DIM design that can affect implementation: 
1. hospital patients will have no active drug 
history when they enter the Pharmacy Subsystem. 
If this is not true, a procedure must exist in 
the Pharmacy Subsystem to create "dummy" current 
medications on the patient medication file to 
represent the previously applied drugs. 
2. hospital patients will have access only to 
77 
pharmacy-issued formulary drugs. 
3. medications charged out of the pharmacy to a 
pdtient have been administered to the patient. 
4. drug8 will be identified to the DIM only by one 
of three valid means:  drug code number. Generic 
Name or current formulary Tradename. 
5. the Pharmacy Subsystem vill contain an on-line 
Medication Order file that will store all new 
Medication Orders that enter the Subsystem, and 
will be available to the DIM. 
6. the Pharmacy Subsystem will contain an on-line 
patient medication file that will contain all 
current patient medications and noted allergies, 
and will be available to the DIM. 
7. both the Medication Order file and the patient 
medication file will contain at least the infor- 
mation specified in this chapter, Section A. 
8. the Pharmacy Subsystem will access the input 
files, extract and format the data as specified 
in this chapter, Section A. 
9. the Pharmacy Subsystem will accept, route and 
format the DIM output as specified in this 
chapter, Section A, to the appropriate output 
devices. 
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10. the Pharmacy Subsystem will contain a routine to 
accept and format as specified, this chapter. 
Section A, on-line requests for drug information, 
and then properly format and output the DIM 
response to the on-line request source. 
11. the Pharmacy Subsystem will contain a routine to 
identify and appropriately limit on-line user- 
access to the DIM and the associated data files. 
If any of these assumptions should prove invalid, it 
will be necessary to reanalyze and redesign the affected 
DIM areas.  Therefore, care should be taken to continu- 
ally examine assumption validity during the implementa- 
tion process. 
D.   Implementation Constraints. 
Several design assumptions:  5, 6, 8, 9, 10, 
11, specified in the preceding section are also imple- 
mentation constraints, since they assume that certain 
Pharmacy Subsystem activities exist for DIM implementa- 
tion.  However, there are several activities common only 
to the DIM that must be considered and planned for: 
1. the DIM data base formulary subset must be 
completed before work can begin on the remaining 
two subsets, since the formulary subset is used 
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to generate data necessary for the initial 
developmental stages of both the drug-interaction 
subset, and the drug information subset. 
2. there are at least seven production programs 
that must be operational to implement the data 
base subsets: 
a. PP1-- formulary subset access program to 
load or modify the subset data. 
b. RP2— formulary subset report program to 
list the subset contents. 
c. PP3— drug interaction subset program to 
compare source data with formulary 
content and extract and load or modify 
formulary-relevant drug-pairs. 
d. PP4— drug interaction subset access 
program to load or modify the subset 
interaction data. 
e. RP5— drug interaction subset report 
program to list the subset contents. 
f. PP6— drug information subset access 
program to load or modify the subset 
drug information data. 
g. RP7— drug information subset report 
program to list the subset contents. 
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3. all information stored in the DIM data base must 
have PTC review and approval before it can be 
utilized. 
4. the DIM Process Section (see Fig. 1.1) must have 
input/output interface capabilities with the 
Pharmacy Subsystem. 
Constraints 2 and 3 may involve significant time poriods 
and should be carefully scheduled in the DIM implementa- 
tion, for they can seriously affect the implementation 
schedule. 
E.   Controls. 
The DIM must not modify any files that it can 
access.  In addition, access to the DIM and associated 
resources must be limited to appropriate personnel: 
1. only DIM data base review group representatives 
must have the capability to access and modify 
the data base with PTC approved corrections or 
updates. 
2. the staff pharmacist may access-only through the 
DIM, the DIM data base, the Pharmacy Subsystem 
Medication Order file, and the Pharmacy Subsystem 
patient medication file. 
3. the hospital physician may access-only: through 
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tho DIM, only the segments of the Pharmacy Sub- 
system Medication Order file and patient medica- 
tion file that apply to hospital patients for 
whom he/she is the attending physician. 
4. At present, only the staff pharmacist or hospital 
physician may be allowed to access the DIM from 
an on-line source. 
Control 1 is necessary to ensure the DIM data 
base integrity, and ensure that the data base contains 
only PTC approved drug data. 
Control 2 allows the staff pharmacist to 
access information required for his/her job function. 
Control 3 limits the hospital physician to 
data that pertains only to his/her patients, and 
maintains the patient privacy that now exists. 
Control 4 is necessary to prevent access to 
the DIM and the associated patient or drug data by un- 
authorized personnel through the on-line sources, which 
may be located in uncontrolled hospital-access areas. 
Proper implementation of these controls will 
ensure data base integrity and authority, and maintain 
patient privacy. 
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P.   Back-Up. 
A manual back-up of the DIM functions that 
pertain to Medication Order validation must be available 
to the staff pharmacist, due to their critical nature. 
The drug-information function is less critical, and 
requires no special consideration other than access to 
Facts t Comparisons (12), the drug information subset 
data source. 
To allow Medication Order validation should 
the DIM or Pharmacy Subsystem fail, two reports are 
necessary: 
1. an accurate patient medication history report. 
This may be generated by the Pharmacy Subsystem 
on an appropriate basis and manually maintained 
in a pharmacy patient file, similar to the 
current Pharmacy Medication Profile.  As drugs 
are issued, they must be noted on the current 
report, and as new reports are issued, they must 
be compared against the superseded manually 
updated reports *to serve as a check on the 
patient medication file.  If the reports concur, 
the earlier report is replaced.  Should a dis- 
crepancy occur, the error source must be identi- 
fied, and either the report error corrected, or 
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a medication file correction request input into 
the Pharmacy Subsystem. 
2. hardcopy Medication Orders. 
With hardcopy Medication Orders and accurate 
patient medication histories, the staff pharmacist can 
manually perform the Medication Order validation procoss, 
and provide effective and simple DIM back-up.  In addi- 
tion, the medication file check will help to maintain 
file accuracy, and detect related errors that may occur 
either within the DIM, or the Pharmacy Subsystem. 
G.  Conversion and Implementation. 
For this discussion, the DIM implementation 
and conversion has been divided into eight major tasks. 
Each task is assumed to include, as appropriate, up to 
six system development functions: 
1. analysis. 
2. design. 
3. programmi ng. 
4. testing. 
5. documentation. 
6. conversion. 
Task definition, overall time requirements, and relative 
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phasing are indicated in Fig. 5.3: 
1. Formulary Subset:  obtain and code data, imple- 
ment production programs PPl, RP2, load and test 
subset.  Due to content simplicity, this data 
base subset requires the least developmental 
effort.  Note that the formulary subset must be 
functional before both remaining subsets may be 
started, since it generates the formulary 
listing required to initiate their development. 
2. Drug Information Subset:  obtain formulary 
generic listing, code associated drug information 
data, implement production programs PP6, RP7, 
load and test subset. 
3. Drug Interaction Subset:  obtain formulary 
generic listing, code source-data drug-pairs, 
implement production programs PP3, PP4, RP5, 
extract relevant drug-pairs, code associated 
interaction data, load and test subset.  Due to 
content complexity and required Pharmacy Thera- 
peutic Committee approval, this subset requires 
the most developmental effort. 
4. Link Subsets: link three subsets into total DIM 
data base, verify that all data base content may 
be accurately accessed by either Drug Code 
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Figure  5.3 
Conversion and   Implementation 
Schedule 
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Number, Generic Name, or current formulary 
Tradcname. 
5. DIM Process Section:  accept Pharmacy Subsystem 
request, identify type, access appropriate files, 
generate profiles, search for reaction/inter- 
action, format and pass output to Pharmacy 
Subsystem. 
6. Medication Order Request Implementation: 
interface DIM I/O with Pharmacy Subsystem Medi- 
cation Order processes, verify that DIM properly 
accepts and identifies Medication Order request, 
generates appropriate warnings, successfully 
passes output. 
7. Drug Information Request Implementation: 
interface DIM I/O with Pharmacy Subsystem drug 
Information request processes, verify that DIM 
properly accepts and identifies drug information 
request, accesses appropriate information, 
properly formats output and successfully passes 
output to Subsystem. 
8. Pharmacy Medication Profile Phase-Out:  as DIM 
Medication Order request operation is verified 
(Task 6) for each pharmacy work-station, imple- 
ment parallel maintenance of hardcopy medication 
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history and manual Pharmacy Medication Profile 
for trial period, then successively phase out 
manual Profile at each work-station. 
This final stop in the formal design process assumes 
that two analyst/programmers will be assigned, full-time, 
to the DIM project in order to assign relative lengths 
to the eight major tasks. 
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CHAPTER 6 
DIM NOCK WALK-THROUGH 
A.  Mock-Dp Objective.      )" 
The DIM mock-up utilized the schematic model. 
Fig. 5.1, developed in the previous chapter to manually 
process sample Medication Orders against theoretical 
patient medication histories that contained allergic and 
interactive entries.  Sample DIM output was generated, 
and examined by pharmacy staff to attain a validity 
measure on: 
1. drug-Family use as the functional drug level to 
detect potential drug interactions and allergic 
reactions. 
2. the extent of potential interaction/reaction 
warnings formulated by the DIM: 
a. potential severity. 
b. suggested mechanism. 
c. drug-management techniques. 
d. technical references. 
Three mock-ups are examined in detail to indicate DIM 
operation for a direct allergic reaction, a potential 
cross-sensitivity reaction, and a potential drug-drug 
0 
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interaction. 
B.  Direct Allergic Reaction. 
For this mock-up, a Medication Order for 
Darvon-65 Compound was processed with a patient medi- 
cation record that contained an allergy note for Aspirin. 
DIM operation, detailed in Fig. 5.1, is summarized: 
a. Medication Order request accepted, identified, 
patient identified, and patient medication 
record obtained from patient medication file. 
b. Patient allergy note generated medication 
history Profile A: 
ALLERGY NOTE   PROFILE A 
Aspirin : Salicylate 
(Salicylic Acid) 
c. Medication Order generated drug-Family profile 
DFP-1: 
MEDICATION 
ORDER     DFP-1 
Darvon-65 : Methadone Narcotic 
(Propxyphen HCl) 
Salicylate 
(Aspirin) 
Acetaminophen Deriv. 
(Phenacetin) 
Xanthine Alkaloid Deriv. 
(Caffeine) 
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d. Match between Profile A and DPP-1 found on 
Salicylate. 
e. Medication Order Warning formated: 
1) Patient; Simulat-1. 
2) Order; Darvon-65 Compound. 
3) Ingjred: Salicylate (Aspirin). 
4) Allergy Note: Aspirin. 
f. Warning passed to Pharmacy Subsystem. 
This Medication Order should be verified with the writ- 
ing physician and modified to a similar drug, such as 
Darvocet-N, that does not contain Aspirin. 
C. Cross-Sensitivity Reaction. 
For this mock-up, a Medication Order for 
Ke8so-Pan was processed with a patient medication record 
that contained an allergy note for Bicillin.  DIM oper- 
ation is summarized: 
a. Same as in preceding example. 
b. Patient allergy note generated medication 
history Profile A: 
ALLERGY NOTE   PROFILE A 
Bicillin : Penicillin Deriv. 
(Bensathine Penicillin). 
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c. Medication Order generated drug-Family profile 
DPP-2: 
MEDICATION 
ORDER      DFP-2 
Kesso-Pan : Penicillin Deriv. 
(Potassium Penicillin) 
d. Match between Profile A and DPP-2 found on 
Penicillin Deriv. 
e. Medication Order Warning formulated: 
1) Patient; Simulat-2. 
2) Order; Kesso-Pan. 
3) Ingred: Penicillin Deriv. 
(Potassium Penicillin) 
4) Allergy Note: Bicillin. 
f. Warning passed to Pharmacy Subsystem. 
A potential allergic reaction was indicated, although 
there is no match on the drug ingredients.  However, 
since both the Medication Order and the allergy note 
belong to the Penicillin Derivative Paaily, and have 
similar chemical structures, an allergic reaction may 
be triggered.  This Medication Order should be verified 
with the writing physician, and possibly modified to a 
non-Penicllin Derviative antibiodic. 
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D.  Drug-Drug Interaction. 
Por this mock-up, a Medication Order for 
Maalox was processed with a patient medication record 
that contained a current entry for Sumycin.  DIM oper- 
ation 'is summarized: 
a. Same as in preceding example. 
b. Patient current medications generated 
medication history profile B: 
CURRENT 
MEDICATION   PROFILE B 
Sumycin : Tetracycline Antibiodic 
(Tetracycline RC1) 
c. Medication Order generated drug-Family profile 
DFP-3: 
MEDICATION 
ORDER      DFP-3 
Maalox : Magnesium Antacid 
(Magnesium OR) 
Aluminum Antacid 
(Aluminum OH) 
d. Data base searched for entry on all possible 
pairs constructed from Profile B and DFP-3. 
Entry found for Tetracycline Antibiodic - 
Magnesium/Aluminum Antacid. 
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e. Medication Order Warning formulated: 
1) Patient; Simulat-3. 
2) Order: Maalox. 
3) Current Med: Sunycin 
(Tetracycline Antibiodic). 
4) Severity: Medium. 
5) Mechanism: Antacids w. divalent, tri- 
valent cations impair aba. oral 
tetracyclines - cation chelation by 
tetracycline. 
6) Management: Administer tetracyclines 
more than 1-2 hrs after Calcium, Al, 
Mg Antacids. 
7) References: ShiIs M.E.:"Some Metabolic 
Aspects of Tetracycline", Clin Pharmacol 
Ther, 3:321, 1962. 
The concurrent application of Maalox and Sumycin may 
decrease the antibiodic effect.  The writing physician 
should be notified of this interaction, and the Medicat- 
ion Order appropriately modified. 
Ten additional drug-drug interactions mocked-up 
in the same manner are tabulated in Table 6.1.  All 
interactions were detected and the appropriate inter- 
action data, referenced to Hanston's Drug Interactions 
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(11) made available.  Supplementary allergic mock-ups 
were not generated, since this DIM process is straight- 
forward . 
E. Mock-Up Results. 
For all test cases, the DIM mock-ups correctly 
identified the potential reaction or interaction, and 
provided appropriate information.  However, certain 
modifications were suggested: 
1. a distinction should be made between an allergic 
and a cross-sensitivity reaction, since the 
former has an occurance probability of nearly 
100%, while the occurance probability of the 
latter is usually much less. This could signifi- 
cantly afftect the manner in which the Medication 
Order is modified. 
2. the detail currently provided for a potential 
drug-drug interaction is probably unnecessary 
for the more widely used drugs.  An initial 
interaction report should identify only: 
• Patient 
• Order 
• Interactive Medication(s) 
• Severity 
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and allow the pharmacist to request the remainder 
of the interaction report on-line, from the 
Pharmacy Subsystem. 
Although no design difficulties appeared in the DIM 
mock-ups, the process was primarily intended to 
illustrate, in detail, how the suggested DIM would 
function.  A formal simulation should be used during 
the later design stages to indicate design parameter 
validity. 
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Table 6.1 
Drug-Drug Interaction Mock-Dps 
SAMPLE 
MEDICATION 
6M>ER 
THEORETICAL 
pAtifert* 
HIS*6RY 
HANSTON (11) 
R»ERRMCR 
Dilantin Lidocaine 8 
Zyloprim Dicumarol 25 
Aminosalicylic 
Acid (PAS) 
Warfarin 25 
Nortriptyline Dicumarol 26 
Desipramine Bethanidine 70 
Doxepin Bethanidine 70 
Neo-synephrine Debrisoquin 72 
Tetracycline Penicillin 105 
Cuemiol Digitoxin 130 
Anectine Digitoxin 132 
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CHAPTER 7 
COST/BENEFIT ANALYSIS 
A.   Development Costa. 
To estimate the cost of DIM development, 
certain assumptions were made: 
1. all DIM processes can be implemented on current 
hardware, since the AST! Computer Center hardware 
utilization factor is well below 100%', and extra 
on-line storage is available. 
2. the pharmacy review group is comprised of two 
professional pharmacy staff members. 
3. the need for Pharmacy Therapeutic Committee 
approval of data base content adds a 10% 
overhead to the pharmacy review group person- 
hours. 
4. the source data for the formulary and drug 
information subsets is currently available in 
the hospital:  present formulary, plus Facts and 
Comparisons. 
5. the cost of the source data for the drug inter- 
action subset is negligible, relative to overall 
DIM cost, since it is available as a customer 
service from major pharmaceutical firms. 
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6. the value of an analyst/programmer or staff 
pharmacist person-hour (p-hr.) is rated at $20 
(salary + overheads). 
7. the computer-time costs to implement malor tasks 
are 10% of the total development cost— repre- 
sented in p-hrs. —for the task. 
8. the formulary size is 1500 drugs. 
9. 1000 interactive drugs-pairs from the source 
data are formulary-relevant. 
With these assumptions, the costs to implement the tasks 
defined in Chapter 5, Section G, may be estimated: 
1. Formulary Subset 
a. review group— analyze, code formulary: 
(1500 drugs)   ._     . 
(26 drugs7hr.) <2 !»«•>  150 p-hrs. 
b. PTC overhead  15 p-hrs. 
c. production program PPl  40 p-hrs. 
d. production program RP2  40 p-hrs. 
e. load & test  100 p-hrs. 
f. computer overhead  35 p-hrs. 
g. total  380 p-hrs. 
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2. Drug Information Subset 
a. review group— extract, code data: 
(1500 drugs)   .-     . 
(15 drugs/hr.) IZ P«"-'   200 p-hrs. 
b. PTC overhead  20 p-hrs. 
c. production program PP6  40 p-hrs. 
d. production program RP7  40 p-hrs. 
e. load (. test  100 p-hrs. 
f. computer time overhead  40 p-hrs. 
g. total  440 p-hrs. 
3. Drug Interaction Subset 
a. review group— extract, code data: 
1) drug-pairs: 
iji!00 ?al5u*   x    (2  !*«■>...   65 p-hrs. (30  pairs/hrT) 
2) interaction data: 
(1000 pairs)   (2     . (lb palfs/nr.) KZ  Pers.j 15Q p_hr8 
b. PTC overhead  20 p-hrs. 
c. production program PP3  40 p-hrs. 
d. production program PP4  40 p-hrs. 
e. production program RP5  40 p-hrs. 
f. load & test  100 p-hrs. 
g. computer overhead  45 p-hrs. 
h. total  500 p-hrs. 
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4. Link Subsets k  Test Data Base  100 p-hrs, 
5. Dill Process Section 
a. input t   format data  150 p-hrs. 
b. process data  ISO p-hrs. 
c. format & output data  ISO p-hrs. 
d. total  450 p-hrs. 
6. Medication Order Request 
Implementation..  150 p-hrs. 
7. Drug Information Request 
Implementation  100 p-hrs, 
8. Pharmacy Medica tion Profile 
Phase-Out  100 p-hr», 
To implement these eight tasks will require 
the resources represented by the total, 2220 p-hrs., 
which at the estimated $20/p-hrs. is approximately 
$44,400, distributed between the data base and process 
section costs: 
• data base:  1420 p-hrs.— $28,400 —64% of total 
• process section:  800 p-hrs.— $16,000 —36% of 
total 
with the greater cost percentage applied to the data 
base development. 
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B.   Operation Coats. 
To estimate the DIM data base maintenance 
costs, a total of 50 drug updates per month of all types 
is assumed: 
a. review group— analyze, code data: 
(50 updates)    (2 pers.) (8 updates/hr.) '.  12.50 p-hrs. 
b. PTC overhead  1.25 p-hrs. 
c. load & test  10.00 p-hrs. 
d. computer overhead  2.50 p-hrs. 
e. total  26.25 p-hrs. 
At $20.00 per p-hr., the estimated cost to process 50 
drug updates per month is $525/month. 
If DIM process section yearly maintenance 
costs are estimated at 20% of the implementation costs, 
the process section monthly costs are: 
(($16,000) (20%))/12 - $265/month, for total DIM operation 
costs of approximately $800/month. 
In summary, the DIM costs, subject to the 
stated assumptions are: 
• implement data base  $28 400 
• implement process section  $jg QQQ 
• total implementation  $44 JQQ 
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• total monthly operation  $800/month 
C.   Tangible Benefits 
The tangible benefits contributed to the 
pharmacy operation by the DIM addition to assist the 
staff pharmacist with medication monitoring has been 
estimated by the Pharmacy Head to be approximately 3 
hours/week/pharmacist saved to manually identify and 
reference a potential drug reaction/interaction.  With 
the current staff of ten pharmacists, this is an estima- 
ted savings of 1560 p-hrs./year, or at $20/p-hr., 
$31,200.  If no other cost benefits are considered, and 
the DIM operation computer-time costs are conservatively 
estimated at 15% of total development costs, the DIM can 
potentially repay its development costs in three years: 
• estimated yearly savings  $31,200 
• estimated yearly costs: 
1. maintenance  $ 9,600 
2. computer time  $ 6,660 
• total yearly benefits  $14,940 
• pay-back period:  $44,400/($15,000/yr.)-2.96 yrs. 
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D.   Intangible Denefits. 
However, there are intangible, or indirect DIM 
benefits that must be considered for a complete cost/ 
benefit picture: 
• increased medication monitoring accuracy. 
• drug information service for the physician. 
• formulary computerization. 
The DIM assistance with medication monitoring will 
ensure that each staff pharmacist will validate Medica- 
tion Orders with complete and accurate drug information. 
This will inherently increase medication monitoring 
accuracy, since it is now possible that new, or obscure 
drug information may not be utilized by the staff phar- 
macist when Medication Orders are filled,  with increased 
medication monitoring accuracy, the potential for drug 
reactions/interactions that can have serious patient 
consequences will be reduced, and this can not only 
decrease the potential danger to the patient, but most 
probably will shorten the number of patient-days 
required for treatment, allow more efficient hospital- 
resource use, and decrease the cost of patient health- 
care. 
The drug information service provided by the 
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the DIM resources to the prescribing physician can 
increase the accuracy of applied patient chemotherapy, 
since the physician will have the ability to verify drug 
application parameters before the Medication Order is 
writtdn.  Again, the physician will have access to 
current drug information that might not normally be 
availablo— a definite possibility, given the dynamic 
nature of applied chemotherapy —that can increase the 
accuracy and efficiency of patient health-care resources 
and techniques. • 
And last, an indirect, but definitely useful 
DIM function can be the use of the DIM data base as a 
data source for a production program to print an ASH 
formulary hardcopy, a task now manually performed. 
Since the DIM data base will always represent the 
current ASH formulary status immediately after a data 
.base update, it may be used to produce a formulary 
listing on a more dynamic basis than the current formu- 
lary update process, which occurs once or twice per 
year.  In addition to decreasing the cost to manually 
revise and print the formulary, the overall formulary 
accuracy can be increased by the shortened revision 
cycle.  These three intangible DIM benefits must be 
added to the cost estimates to create the complete 
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cost/benefit picture for DIM implementation, which 
appears highly favorable. 
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CHAPTER 8 
SUMMARY 
This project systematically examined several 
design parameters for a Drug Information Module to apply 
computer techniques and provide medication monitoring and 
general formulary drug information within the framework 
of a computerized Pharmacy Subsystem.  The study defined: 
• the primary DIM user 
• DIM-related user processes 
• the information required for user processes 
and generated initial design specifications that would 
result in a Drug Information Module to satisfy user 
needs. 
The study indicates that potential does exist 
for successful implementation of computer techniques to 
assist the hospital pharmacy deal with the large volume 
of drug information that must be processed for each 
hospital in-patient, and provides direction for the 
feasible implementation of a process module to aid with 
two important areas: medication monitoring, and 
pre-prescription drug information. 
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APPENDIX A 
ASH - Allentown-Sacred Heart Hospital. 
CPS - Computerized Pharmacy Subsystem. 
DFP - Drug Family Profile.  A summary of the drug- 
Families represented by the active ingredients 
of a drug.  Created from the Medication Order. 
DIM - Drug Information Module. 
HIS - Computerized Hospital Information System that 
encompasses several departments. 
OES - Computerized Order Fntry System to capture 
physician orders as close to the origination 
point as possible. 
PPl - Production program to access and load, or modify, 
the formulary subset in the DIM data base. 
PP3 - Production program to identify and load into the 
formulary subset the relevant drug-pairo from 
the data source. 
PP4 - Production program to access and load, or modify, 
the drug-interaction subset in the DIM data base. 
PP6 - Production program to access and load, or modify, 
the drug-information subset in the DIM data base. 
PTC - Pharmacy Theraputic Committee responsible for 
the review of all formulary changes at ASH 
Hospital. 
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RP2 - Production program to list the formulary subset 
of the DIM data base. 
RP5 - Production program to list the drug-interaction 
subset of the DIM data base. 
RP7 - 'Production program to list the drug-information 
subset of the DIM data base. 
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